The 11th-hour attempt by Novo to snatch away Metsera, which Pfizer had agreed to buy in September, has upended debate around ...

For Novo, it marks the boldest move yet for recently appointed CEO Maziar Mike Doustdar. In response to a slowdown in sales ...

Palantir lifted its 2025 revenue guidance and Pfizer has filed a second lawsuit against Novo Nordisk and obesity drug ...

Pfizer filed a second lawsuit on Monday accusing Danish drugmaker Novo Nordisk of structuring its $9 billion bid for Metsera ...

Pfizer insists that Novo Nordisk’s unsolicited offer to acquire Metsera is an effort from the Danish pharma to “suppress ...

Novo Nordisk's new CEO is set to face intense investor scrutiny this week as the Wegovy-maker shakes up its board and pursues ...

Pfizer also has set its sights on becoming a giant in oncology, and to support this, completed the acquisition of Seagen in 2023. Two of Seagen's products in the most recent quarter delivered ...

The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

The lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by ...

Novo Nordisk ups its bid to acquire Metsera, intensifying the obesity drug market race and challenging Pfizer.

Marc Filippino Good morning from the Financial Times. Today is Tuesday, November 4th, and this is your FT News Briefing.